Marc Grasso - 13 Mar 2026 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: KYTX
Reported as of: 13 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 16:30:36 UTC
Prior SEC filing: 01 Jul 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Marc Grasso

Key filing fact

Marc Grasso filed Form 4 for Kyverna Therapeutics, Inc. (KYTX) on 17 Mar 2026.

Key facts

This page summarizes Marc Grasso's Form 4 filing for Kyverna Therapeutics, Inc. (KYTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 01 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001748894 Primary reporting owner

GRASSO MARC

Relationship: Chief Financial Officer
Address: C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON STREET, SUITE 550, EMERYVILLE
Signature: By: /s/ Marc Grasso
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYTX transaction

Common Stock

Award

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 13 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +65,000
Change %
Price: $0.000000^*
Shares after: 65,000
Date: 13 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $8.95
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Footnote F2

1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.